**Core Concept**
Polycythemia rubra vera (PRV) is a myeloproliferative disorder characterized by excessive production of red blood cells, white blood cells, and platelets. Systemic administration of a radioisotope is used to assess and manage this condition.

**Why the Correct Answer is Right**
In PRV, the bone marrow produces an excessive number of red blood cells, which can lead to increased viscosity and risk of thrombosis. To manage this condition, the patient is given a systemic dose of radioactive phosphorus (32P or 33P). This radioisotope selectively targets and destroys the rapidly dividing bone marrow cells, thereby reducing the production of red blood cells. The mechanism of action involves incorporation of the radioisotope into the DNA of the bone marrow cells, leading to cell death due to radiation-induced damage.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because 131I is a radioisotope used primarily for thyroid ablation or diagnosis, not for treating PRV.
* **Option B:** This option is incorrect because 99mTc is a technetium isotope used for nuclear medicine imaging, not for systemic treatment of PRV.
* **Option C:** This option is incorrect because 223Ra is a radioisotope used for treating bone metastases in prostate cancer, not for PRV.

**Clinical Pearl / High-Yield Fact**
Remember that radioactive phosphorus is used to selectively target and destroy rapidly dividing bone marrow cells, making it a useful treatment option for PRV.

**Correct Answer:** C. 223Ra is incorrect so we will use 32P or 33P